Interstitial Lung Disease Panel
Use
This test is intended for individuals who have characteristics suggesting interstitial lung disease or who have a family history of interstitial lung disease or idiopathic pulmonary fibrosis. It can aid in diagnosing specific genetic causes of interstitial lung disease, which may influence management and treatment strategies. The test can help identify pathogenic variants in 24 genes known to be associated with interstitial lung disease, providing insights into the inheritance pattern and aiding in the confirmation of a clinical diagnosis.
Special Instructions
Special instructions include completing the clinical features checklist and providing detailed clinical notes to aid in the interpretation of variants. STAT testing is available, which expedites the turnaround time but adds an additional cost. Orders must be placed by a qualified healthcare provider, and signed consent forms are required, documenting the patient's and any family members' informed consent for the test.
Limitations
The test may not detect all genetic variants associated with interstitial lung disease, and false negatives are possible. Variants of uncertain significance may be found, and the clinical relevance of these findings will depend on additional clinical and familial information. Not all types of genetic variations, such as large deletions, duplications, or low-level mosaicisms, may be detected. Results may be inconclusive if poor-quality DNA is provided. The test's sensitivity and specificity are reliant on current genomic knowledge, which may evolve over time.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided